AOD-9604 in Gangotri — Fat Loss Peptide Research Guide
AOD-9604 research guide for Gangotri. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Gangotri trying to locate AOD-9604, the first thing to know is that this compound is distributed via specialist online vendors. The benefit of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers more rigorous quality data than local retail ever could. Separating quality AOD-9604 from the rest of the market depends on three things: an HPLC chromatogram showing ≥98% purity, mass spec data confirming the correct molecular weight, and a batch-specific endotoxin panel. This guide gives Gangotri researchers the practical tools to assess vendor quality rigorously and source high-purity AOD-9604 with confidence.
How AOD-9604 Works — Mechanisms & Research
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Gangotri studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Evaluate AOD-9604 Vendors
Before looking at individual vendors, build a clear picture of what a proper COA looks like — so you can identify whether a supplier meets the standard. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from microbial contamination can trigger serious immune reactions even at trace quantities. For Gangotri researchers evaluating unfamiliar vendors: a test quantity before committing to research volumes before scaling up your order is what experienced peptide researchers consistently do. For Gangotri researchers making a first AOD-9604 purchase: verify the vendor against this framework, start with a modest quantity, and check that batch numbers on your vial match the COA before use.
Order AOD-9604 — ships to Gangotri
COA-verified · International tracking · Research grade
Research compound status for AOD-9604 means the safety evidence is drawn from animal studies, in-vitro work, and limited human observations — rather than the controlled trials that generate pharmaceutical safety profiles. Storage requirements for AOD-9604: lyophilised powder at −20°C, reconstituted solution stored refrigerated at 2-8°C and finished within 30 days of reconstitution; reconstitute only with bacteriostatic water. Endotoxin testing in the AOD-9604 COA is absolutely required — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at trace quantities, and no cost saving makes omitting this acceptable. Researchers using AOD-9604 alongside other research compounds should examine published studies for potential interaction data before running stacked compound experiments.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
